Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Shanghai Haohai Biological Technology Co., Ltd. Class H ( (HK:6826) ) has shared an update.
Shanghai Haohai Biological Technology Co., Ltd. announced the acquisition of the remaining 20% equity interest in a previously non-wholly owned subsidiary, making it a fully owned subsidiary. This transaction, valued at RMB74,000,000, consolidates the company’s control over the subsidiary, potentially enhancing its operational efficiency and financial performance. The acquisition is classified as a connected transaction under Hong Kong’s Listing Rules, but it is exempt from the requirement for independent shareholders’ approval due to the applicable percentage ratios.
The most recent analyst rating on (HK:6826) stock is a Buy with a HK$30.00 price target. To see the full list of analyst forecasts on Shanghai Haohai Biological Technology Co., Ltd. Class H stock, see the HK:6826 Stock Forecast page.
More about Shanghai Haohai Biological Technology Co., Ltd. Class H
Shanghai Haohai Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and production of biological materials and medical devices. The company is known for its innovative solutions in ophthalmology, orthopedics, and wound care, catering to both domestic and international markets.
Average Trading Volume: 374,882
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.74B
See more insights into 6826 stock on TipRanks’ Stock Analysis page.